Energy Dome's CO2 Battery™ to Revolutionize U.S. Energy Landscape With First Installation Slated for 2026
A groundbreaking development in sustainable energy storage is on the horizon for Columbia County, Wisconsin, U.S., spearheaded by Alliant Energy in collaboration with Energy Dome and other key stakeholders. Alliant Energy has just announced its selection to receive a federal grant of up to approximately $30 million from the U.S. Department of Energy's Office of Clean Energy Demonstrations (OCED) for the pioneering Columbia Energy Storage Project, a proposed 200-megawatt hour energy storage system, based on Energy Dome’s signature technology: the CO2 Battery™.
This visionary battery system, aptly named the “Columbia Energy Storage Project”, is poised to be a trailblazer in the United States, marking a pivotal stride towards a more sustainable, reliable, and cost-effective energy future.
Claudio Spadacini, CEO of Energy Dome, declared: “I’m honored to be part of this remarkable journey alongside Alliant Energy. The Columbia Energy Storage Project marks the genesis of a new era, where the CO2 Battery™ will be the cornerstone of a greener and more efficient energy landscape. Thanks to the decision made by the DoE, we are sure this project is going to be the first step in a journey that will see the widespread adoption of our technology, setting the stage for numerous other installations to follow suit. Our CO2 Battery™ is a tangible solution, available today, that will change how sustainable long-duration energy storage is adopted, making it more accessible and impactful for communities nationwide. Together with Alliant Energy, we are shaping a cleaner and brighter tomorrow.”
The facility is planned for construction south of Portage, Wisconsin, in the Town of Pacific, near the current Columbia Energy Center. Alliant Energy anticipates submitting project plans to the Wisconsin Public Service Commission in the first half of 2024, with construction slated to commence in 2025 and expected completion in 2026.
About Energy Dome
Energy Dome is revolutionizing energy storage and enabling grid decarbonization by making solar and wind power dispatchable 24/7. The company invented and developed the CO2 Battery™, a long-duration energy storage system that makes long-duration energy storage viable globally today. The properties of carbon dioxide allow the system to store energy efficiently and cost-effectively, with a modular and site-independent footprint. CO2 Batteries™ use readily available, off-the-shelf components from reliable, existing supply chains, providing a scalable pathway to store massive amounts of intermittent renewable energy and accelerate the energy transition. For more information, please visit energydome.com.
About Alliant Energy
Alliant Energy Corporation (NASDAQ: LNT) provides regulated energy service to 995,000 electric and 425,000 natural gas customers across Iowa and Wisconsin. Alliant Energy's mission is to deliver energy solutions and exceptional service customers and communities count on – safely, efficiently and responsibly. Interstate Power and Light Company (IPL) and Wisconsin Power and Light Company (WPL) are Alliant Energy's two public energy companies. Alliant Energy is a component of the Nasdaq CRD Sustainability Index, Bloomberg’s Gender-Equality Index, and the S&P 500. For more information, visit alliantenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230922702415/en/
Contact information
Mario Torchio - m.torchio@energydome.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 13:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 12:12:00 EEST | Press release
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021806533/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain. PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease2. To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial3 that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 11:00:00 EEST | Press release
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom